%0 Journal Article
%A Sosero, Yuri L
%A Bandres-Ciga, Sara
%A Ferwerda, Bart
%A Tocino, Maria T P
%A Belloso, Dìaz R
%A Gómez-Garre, Pilar
%A Faouzi, Johann
%A Taba, Pille
%A Pavelka, Lukas
%A Marques, Tainà M
%A Gomes, Clarissa P C
%A Kolodkin, Alexey
%A May, Patrick
%A Milanowski, Lukasz M
%A Wszolek, Zbigniew K
%A Uitti, Ryan J
%A Heutink, Peter
%A van Hilten, Jacobus J
%A Simon, David K
%A Eberly, Shirley
%A Alvarez, Ignacio
%A Krohn, Lynne
%A Yu, Eric
%A Freeman, Kathryn
%A Rudakou, Uladzislau
%A Ruskey, Jennifer A
%A Asayesh, Farnaz
%A Menéndez-Gonzàlez, Manuel
%A Pastor, Pau
%A Ross, Owen A
%A Krüger, Rejko
%A Corvol, Jean-Christophe
%A Koks, Sulev
%A Mir, Pablo
%A De Bie, Rob M A
%A Iwaki, Hirotaka
%A Gan-Or, Ziv
%T Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
%J Movement disorders
%V 39
%N 10
%@ 0885-3185
%C New York, NY
%I Wiley
%M DZNE-2024-01240
%P 1773 - 1783
%D 2024
%X Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2.Our goal was to investigate the effects of genetic variants on risk and time to LID.We performed a genome-wide association study (GWAS) and analyses focused on GBA1 and LRRK2 variants. We also calculated polygenic risk scores (PRS) including risk variants for PD and variants in genes involved in the dopaminergic transmission pathway. To test the influence of genetics on LID risk we used logistic regression, and to examine its impact on time to LID we performed Cox regression including 1612 PD patients with and 3175 without LID.We found that GBA1 variants were associated with LID risk (odds ratio [OR] = 1.65; 95
%K Humans
%K Levodopa: adverse effects
%K Parkinson Disease: genetics
%K Parkinson Disease: drug therapy
%K Dyskinesia, Drug-Induced: genetics
%K Male
%K Female
%K Aged
%K Leucine-Rich Repeat Serine-Threonine Protein Kinase-2: genetics
%K Glucosylceramidase: genetics
%K Middle Aged
%K Genome-Wide Association Study
%K Dopamine: metabolism
%K Antiparkinson Agents: adverse effects
%K Genetic Predisposition to Disease: genetics
%K Polymorphism, Single Nucleotide: genetics
%K GBA1 (Other)
%K LRRK2 (Other)
%K Parkinson's disease (Other)
%K dopamine (Other)
%K levodopa‐induced dyskinesia (Other)
%K Levodopa (NLM Chemicals)
%K Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 (NLM Chemicals)
%K Glucosylceramidase (NLM Chemicals)
%K LRRK2 protein, human (NLM Chemicals)
%K Dopamine (NLM Chemicals)
%K GBA protein, human (NLM Chemicals)
%K Antiparkinson Agents (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%2 pmc:PMC11490412
%$ pmid:39132902
%R 10.1002/mds.29960
%U https://pub.dzne.de/record/272822